Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

recently gave a positive opinion recommending approval of seladelpar for the treatment of PBC in the EU. A final decision is anticipated in the first quarter of 2025. Gilead Sciences recently ...

Seladelpar belongs to a group of medicines ... Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

“Gilead delivered another exceptionally strong ... This was primarily driven by the launch of Livdelzi® (seladelpar) in primary biliary cholangitis (“PBC”), and increased demand in products ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead is also evaluating investigational regimens for HIV with once-daily, once-weekly and twice-yearly dosing frequencies. In August 2024, the FDA granted accelerated approval to seladelpar for ...